Καταχωρήθηκε: Τετάρτη 22 Φεβ 2023
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40mins

Axicabtagene ciloleucel is an engineered autologous anti-CD19 chimeric
antigen receptor T cell therapy being developed for patients with refractory aggressive B-cell lymphoma. The product is manufactured in a central
facility from cellular starting material containing a patient’s own T cells
into which a chimeric antigen receptor transgene is directly introduced.
This cellular starting material is highly variable from donor to donor and
provides the single largest source of variability associated with the production process. Nonetheless, a robust manufacturing and distribution
process was developed based on process understanding and appropriate
process controls. Process characterization revealed process parameters
that affect quality attributes, allowing appropriate control measures to
be implemented. Process comparability criteria were also established as
another mechanism to ensure process consistency as new manufacturing sites were introduced. A relationship between cellular characteristics
of the incoming cellular starting material, cell growth and performance
during manufacturing, and the ultimate product characteristics after administration to patients is also beginning to come into focus.

Read the full article on Overcoming Challenges for Engineered Autologous T Cell Therapies


Τηλέφωνα Επικοινωνίας:


Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)


βρείτε μας στο χάρτη


Login / Sitemap


Copyright © 2015 - 2024 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας